Announcement on New and Cumulative Litigation and Arbitration Cases
The company and all members of the board guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or major omissions.
Important Content Reminder:
New Litigation:
Recently, the company received a "Civil Complaint" delivered by the Changchun New District People's Court. The case involves a financial loan contract dispute filed by Jilin Jiutai Rural Commercial Bank Changchun Branch and Jilin Dehui Rural Commercial Bank against Jilin Zixin Pharmaceutical Co., Ltd. (hereinafter referred to as "the company"). The case is currently under trial and has not yet been adjudicated. The company and its subsidiaries are defendants, with an amount in dispute of 200 million RMB, including principal, interest, and overdue interest.
Impact on the Listed Company's Profit and Loss:
The case is currently in the trial stage, and no judgment has been made, leading to uncertainty regarding its impact on the company's current or future profits, making it impossible to accurately estimate the specific impact amount at this time.
Cumulative Litigation Progress
- The company recently received a civil judgment from the Nanquan District People's Court of Changchun City, Jilin Province (2022) Ji 0102 Minchu 6550, regarding a financial loan contract dispute between Jilin Nong'an Rural Commercial Bank Satellite Square Branch and the company's subsidiary, Jilin Zixin Pharmaceutical Co., Ltd. For details, please refer to the announcement disclosed by the company on September 17, 2022, titled "Announcement on New Litigation, Litigation Progress, and Cumulative Litigation and Arbitration" (Announcement No.: 2022-087); the announcement disclosed on January 31, 2023, titled "Announcement on Cumulative Litigation and Arbitration Progress" (Announcement No.: 2023-015); and the announcement disclosed on April 18, 2023, titled "Announcement on New Litigation and Cumulative Litigation and Arbitration" (Announcement No.: 2023-025).
The judgment is as follows:
(1) Jilin Zixin Pharmaceutical Co., Ltd. shall immediately repay Jilin Nong'an Rural Commercial Bank Satellite Square Branch the outstanding loan principal of 28,707,582.16 RMB, interest of 1,672,647.59 RMB, penalty interest of 3,293,329.59 RMB, compound interest of 360,696.3 RMB, and subsequent penalty interest and compound interest (penalty interest calculated based on the principal of 28,707,582.16 RMB, and compound interest calculated based on the interest of 1,672,647.59 RMB, from February 9, 2023, until the actual payment date, at an annual interest rate of 5.8% plus 50%);
(2) Jilin Zixin Pharmaceutical Co., Ltd. shall immediately pay Jilin Nong'an Rural Commercial Bank Satellite Square Branch a lawyer's fee of 100,000 RMB;
(3) Dunhua Kangping Investment Co., Ltd. shall bear joint and several liability for the above debts of Jilin Zixin Pharmaceutical Co., Ltd.;
(4) Jilin Zixin Pharmaceutical Co., Ltd. shall bear joint and several liability for the above debts of Jilin Zixin Pharmaceutical Co., Ltd.;
(5) Bian Zhenli shall bear joint and several liability for the above debts of Jilin Zixin Pharmaceutical Co., Ltd.;
(6) Feng Youshun shall bear joint and several liability for the above debts of Jilin Zixin Pharmaceutical Co., Ltd.;
(7) Guo Chunhui shall bear joint and several liability for the above debts of Jilin Zixin Pharmaceutical Co., Ltd.
If the obligations to pay money as specified in this judgment are not fulfilled within the designated period, the debtor shall pay double the interest on the delayed performance of the debt in accordance with Article 260 of the Civil Procedure Law of the People's Republic of China. The case acceptance fee of 198,350 RMB shall be borne by Jilin Zixin Pharmaceutical Co., Ltd., Dunhua Kangping Investment Co., Ltd., Jilin Zixin Pharmaceutical Co., Ltd., Bian Zhenli, Feng Youshun, and Guo Chunhui.